EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Does the Evidence Support High-Dose Liposomal Amphotericin B in the Treatment of Mucormycosis?

Russell E Lewis iD, Dimitrios P Kontoyiannis iD

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag336 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Russell E Lewis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, University of Padua, Padua, Italy. Hauptthemen laut MEDLINE: Mucormycosis, Amphotericin B, Antifungal Agents. Die Arbeit nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Guidelines recommend liposomal amphotericin B (L-AMB) at 5–10 mg/kg/day as first-line therapy for invasive mucormycosis, but whether doses exceeding 5–6 mg/kg/day improve outcomes enough to justify added nephrotoxicity and cost remains unclear. We critically appraised pharmacokinetic, preclinical, and clinical evidence from 58 publications, defining standard-dose L-AMB as 5–6 mg/kg/day and high-dose (HD) L-AMB as >6 mg/kg/day. Animal models show dose-dependent efficacy, but the only prospective trial (Ambizygo) examining HD-L-AMB was a single-arm pilot trial whose response rates were similar to historical 5 mg/kg/day cohorts. Retrospective studies have not found survival benefit favoring HD L-AMB, with consistently higher rates of nephrotoxicity. Saturable pharmacokinetics and altered liposome distribution at doses >10 mg/kg/day may explain this lack of benefit. Routine dose escalation beyond 5–6 mg/kg/day is not supported by current evidence; early diagnosis, surgical debridement, and reversal of immunosuppression appear more critical. However, selected cases may still warrant higher L-AMB doses based on individualized risk–benefit assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucormycosisAmphotericin BAntifungal AgentsHumansAnimalsDose-Response Relationship, Drug

Stichwörter der Autor:innen

high-doseliposomal amphotericin Bmucormycosisnephrotoxicitypharmacokinetics

Substanzen

Amphotericin BAntifungal Agentsliposomal amphotericin B

Autor:innen und Institutionen

  • Department of Molecular Medicine, University of Padua, Padua, Italy.
  • Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Russell E Lewis, Dimitrios P Kontoyiannis

Zitieren

APA

Lewis, R. E., & Kontoyiannis, D. P. (2026). Does the Evidence Support High-Dose Liposomal Amphotericin B in the Treatment of Mucormycosis?. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag336

Vancouver

Lewis RE, Kontoyiannis DP. Does the Evidence Support High-Dose Liposomal Amphotericin B in the Treatment of Mucormycosis?. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag336

BibTeX
@article{Lewis2026,
  author = {Lewis, Russell E and Kontoyiannis, Dimitrios P},
  title = {Does the Evidence Support High-Dose Liposomal Amphotericin B in the Treatment of Mucormycosis?},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag336}
}
Kostenlos starten →